Antidiabetic drugs as antihypertensives: New data on the horizon

Current Vascular Pharmacology

Volumn 16, Issue 1, 2018, Pages 70-78

  Mamakou, Vassiliki ^a,b   Eleftheriadou, Ioanna ^a   Katsiki, Niki ^c   Makrilakis, Konstantinos ^a   Tsioufis, Konstantinos ^a   Tentolouris, Nikolaos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Psychiatric Hospital Dromokaiteio   (Greece)

^c ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

Author keywords

Antidiabetic medications; Blood pressure; Cardiovascular disease; CV; CVD; Type 2 diabetes mellitus

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; CANAGLIFLOZIN; CHLORPROPAMIDE; DAPAGLIFLOZIN; EMPAGLIFLOZIN; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; IPRAGLIFLOZIN; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; NATEGLINIDE; PIOGLITAZONE; REMOGLIFLOZIN ETABONATE; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SEMAGLUTIDE; SITAGLIPTIN; TOLBUTAMIDE; VILDAGLIPTIN; ANTIHYPERTENSIVE AGENT;

BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; META ANALYSIS (TOPIC); MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE; COMPLICATION; DRUG EFFECT; HYPERTENSION; PATHOPHYSIOLOGY;

ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS;

EID: 85042214577     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161115666171010122332     Document Type: Review

References (53)

1. Ryden L, Grant PJ, Anker SD, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The task force on diabetes, pre-diabetes, and cardiovascular diseases of the European society of cardiology (ESC) and developed in collaboration with the European association for the Study of diabetes (EASD). Eur Heart J 2013; 34: 3035-87.
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-53.
3. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-89.
4. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317: 703-13.
5. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-71.
6. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-28.
7. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311-22.
8. Marso SP, Bain SC, Consoli A, et al. semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375: 1834-44.
9. American Diabetes Association. Approaches to Glycemic Treatment. Diabetes Care 2016; 38 (Suppl 1): S41-8.
10. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK prospective diabetes study (UKPDS) group. Lancet 1998; 352: 854-65.
11. Wulffele MG, Kooy A, de Zeeuw D, Stehouwer CD, Gansevoort RT. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: A systematic review. J Intern Med 2004; 256: 1-14.
12. Anabtawi A, Miles JM. Metformin: Non-glycemic effects and potential novel indications. Endocr Pract 2016; Epub ahead of print.
13. Wulffele MG, Kooy A, Lehert P, et al. Does metformin decrease blood pressure in patients with Type 2 diabetes intensively treated with insulin? Diabet Med 2005; 22: 907-13.
14. He H, Zhao Z, Chen J, et al. Metformin-based treatment for obe-sity-related hypertension: A randomized, double-blind, placebo-controlled trial. J Hypertens 2012; 30: 1430-9.
15. Lexis CP, van der Horst-Schrivers AN, Lipsic E, et al. The effect of metformin on cardiovascular risk profile in patients without diabetes presenting with acute myocardial infarction: Data from the glycometabolic intervention as adjunct to primary coronary intervention in ST elevation myocardial infarction (GIPS-III) trial. BMJ Open Diabetes Res Care 2015; 3: e000090.
16. A study of the effects of hypoglycemia agents on vascular complications in patients with adult-onset diabetes. VI. Supplementary report on nonfatal events in patients treated with tolbutamide. Diabetes 1976; 25: 1129-53.
17. Schwartz TB, Meinert CL. The UGDP controversy: Thirty-four years of contentious ambiguity laid to rest. Perspect Biol Med 2004; 47: 564-74.
18. Sundaresan P, Lykos D, Daher A, et al. Comparative effects of glibenclamide and metformin on ambulatory blood pressure and cardiovascular reactivity in NIDDM. Diabetes Care 1997; 20: 692-7.
19. Group NS, Holman RR, Haffner SM, et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362: 1463-76.
20. Derosa G, D'Angelo A, Fogari E, et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. J Clin Pharm Ther 2009; 34: 13-23.
21. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macrovascular events): A randomised controlled trial. Lancet 2005; 366: 1279-89.
22. Konrad T, Lubben G, Franzen C. Pioglitazone lowers blood pressure in hypertensive patients with type 2 diabetes mellitus: an open, multicentre, observational study. Clin Drug Investig 2005; 25: 337-40.
23. Qayyum R, Adomaityte J. A meta-analysis of the effect of thia-zolidinediones on blood pressure. J Clin Hypertens 2006; 8: 19-28.
24. DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med; 364: 1104-15.
25. Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N Engl J Med 2016; 374: 1321-31.
26. Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290: 486-94.
27. Hanefeld M, Cagatay M, Petrowitsch T, et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: Meta-analysis of seven long-term studies. Eur Heart J 2004; 25: 10-6.
28. Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, De Grauw WJ. Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database Syst Rev 2006: CD005061.
29. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-26.
30. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327-35.
31. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373: 232-42.
32. Zhang X, Zhao Q. Effects of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type 2 diabetes: A systematic review and meta-analysis. J Hypertens 2016; 34: 167-75.
33. von Eynatten M, Gong Y, Emser A, Woerle HJ. Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: A pooled analysis of six phase III clinical trials. Cardiovasc Diabetol 2013; 12: 60.
34. Cobble ME, Frederich R. Saxagliptin for the treatment of type 2 diabetes mellitus: Assessing cardiovascular data. Cardiovasc Diabetol 2012; 11: 6.
35. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015; 373: 2247-57.
36. Wang B, Zhong J, Lin H, et al. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: A meta-analysis of clinical trials. Diabetes Obes Metab 2013; 15: 737-49.
37. Robinson LE, Holt TA, Rees K, Randeva HS, O'Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: Systematic review and meta-analysis. BMJ Open 2013; 3(1): e001986.
38. Sun F, Wu S, Guo S, et al. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis. Diabetes Res Clin Pract 2015; 110: 26-37.
39. Abdul-Ghani M, Del Prato S, Chilton R, DeFronzo RA. SGLT2 inhibitors and cardiovascular risk: Lessons learned from the EMPA-REG OUTCOME study. Diabetes Care 2016; 39: 717-25.
40. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375: 323-34.
41. Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 2015; 38: 420-8.
42. Majewski C, Bakris GL. Blood pressure reduction: An added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes. Diabetes Care 2015; 38: 429-30.
43. Sattar N, McLaren J, Kristensen SL, Preiss D, McMurray JJ. Erratum to: SGLT2 Inhibition and cardiovascular events: Why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia 2016; 59: 1573-74.
44. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALL-HAT). JAMA 2002; 288(23): 2981-97.
45. Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: A "Thrifty Substrate" hypothesis. Diabetes Care 2016; 39: 1108-14.
46. Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME Study? A unifying hypothesis. Diabetes Care 2016; 39: 1115-22.
47. Baker WL, Smyth LR, Riche DM, et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis. J Am Soc Hypertens 2014; 8: 262-75.
48. Qaseem A, Humphrey LL, Sweet DE, et al. Oral pharmacologic treatment of type 2 diabetes mellitus: A clinical practice guideline from the American college of physicians. Ann Intern Med 2012; 156: 218-31.
49. Frias JP, Guja C, Hardy E, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): A 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 2016; 4: 1004-16.
50. American Diabetes Association. 8. pharmacologic approaches to glycemic treatment. Diabetes Care 2017; 40(Suppl 1): 64-74.
51. Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367: 319-28.
52. Davies MJ, Donnelly R, Barnett AH, et al. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: Results of the helping evaluate exenatide in patients with diabetes compared with long-acting insulin (HEELA) study. Diabetes Obes Metab 2009; 11: 1153-62.
53. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-13.